	US 12,102,620 B2
	Combination therapy for the treatment of mastocytosis
Daniel L. Flynn, Waltham, MA (US); Bryan D. Smith, Waltham, MA (US); and Anu Gupta, Waltham, MA (US)
Assigned to Deciphera Pharmaceuticals, LLC, Waltham, MA (US)
Filed by Deciphera Pharmaceuticals, LLC, Waltham, MA (US)
Filed on Jul. 30, 2020, as Appl. No. 16/943,871.
Application 16/943,871 is a continuation of application No. PCT/US2019/016161, filed on Jan. 31, 2019.
Claims priority of provisional application 62/624,453, filed on Jan. 31, 2018.
Prior Publication US 2020/0352920 A1, Nov. 12, 2020
Int. Cl. A61K 31/4375 (2006.01); A61K 31/4184 (2006.01); A61K 31/4439 (2006.01); A61K 31/4523 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); A61K 45/06 (2006.01); A61P 43/00 (2006.01)

CPC A61K 31/4375 (2013.01) [A61K 31/4184 (2013.01); A61K 31/4439 (2013.01); A61K 31/4523 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61K 45/06 (2013.01); A61P 43/00 (2018.01)]

12 Claims

1. A method of treating mastocytosis in a patient in need thereof, comprising administering to the patient:

an effective amount of a c-KIT inhibitor, wherein the c-KIT inhibitor is 1-[4-bromo-5-[1- ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea, or a pharmaceutically acceptable salt thereof; and

an effective amount of one or more MAPKAP pathway inhibitors selected from the group consisting of trametinib, cobimetinib, binimetinib, and ulixertinib.